|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
EP2183232B1
(en)
|
2007-08-02 |
2013-03-06 |
Amgen, Inc |
Pi3 kinase modulators and methods of use
|
|
US20100311736A1
(en)
*
|
2007-10-22 |
2010-12-09 |
Glaxosmithkline Llc |
Pyridosulfonamide derivatives as p13 kinase inhibitors
|
|
EP2231661A1
(en)
|
2007-12-19 |
2010-09-29 |
Amgen, Inc. |
Inhibitors of pi3 kinase
|
|
MX315904B
(es)
|
2008-05-30 |
2013-11-29 |
Amgen Inc |
Inhibidores de fosfoinosituro-3 cinasa.
|
|
WO2009157196A1
(ja)
*
|
2008-06-25 |
2009-12-30 |
武田薬品工業株式会社 |
アミド化合物
|
|
KR20110058866A
(ko)
|
2008-09-02 |
2011-06-01 |
노파르티스 아게 |
비시클릭 키나제 억제제
|
|
EP2370424A1
(en)
|
2008-11-10 |
2011-10-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2010059549A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
|
EP2376485B1
(en)
|
2008-12-19 |
2017-12-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazine derivatives useful as inhibitors of atr kinase
|
|
SG172353A1
(en)
*
|
2008-12-23 |
2011-07-28 |
Abbott Lab |
Anti-viral compounds
|
|
RU2505540C2
(ru)
|
2008-12-23 |
2014-01-27 |
Эббви Инк. |
Антивирусные соединения
|
|
EP2387564A1
(en)
|
2009-01-15 |
2011-11-23 |
Rutgers, The State University of New Jersey |
Benzo ýc¨phenanthridines as antimicrobial agents
|
|
AU2010231162B2
(en)
|
2009-04-02 |
2014-12-11 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
|
|
US9278922B2
(en)
|
2009-04-15 |
2016-03-08 |
Abbvie Inc. |
Anti-viral compounds
|
|
WO2010127307A1
(en)
|
2009-04-30 |
2010-11-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
DK2429995T3
(da)
|
2009-05-15 |
2014-04-22 |
Novartis Ag |
Arylpyridiner som aldosteronsyntaseinhibitorer
|
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
|
US8765940B2
(en)
*
|
2009-06-25 |
2014-07-01 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
NZ598220A
(en)
|
2009-08-17 |
2014-02-28 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
WO2011021678A1
(ja)
*
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
LT2473487T
(lt)
|
2009-09-03 |
2017-01-10 |
Bristol-Myers Squibb Company |
Chinazolinai kaip kalio jonų kanalų inhibitoriai
|
|
PH12012500491A1
(en)
*
|
2009-09-09 |
2018-03-21 |
Celgene Avilomics Res Inc |
P13 kinase inhibitors and uses thereof
|
|
SG179172A1
(en)
|
2009-09-16 |
2012-04-27 |
Avila Therapeutics Inc |
Protein kinase conjugates and inhibitors
|
|
MX2012003779A
(es)
*
|
2009-09-28 |
2012-06-01 |
Glaxosmithkline Llc |
Combinacion.
|
|
CN102665720A
(zh)
*
|
2009-10-12 |
2012-09-12 |
葛兰素史密斯克莱有限责任公司 |
组合
|
|
WO2011051958A1
(en)
|
2009-10-30 |
2011-05-05 |
E.I. Du Pont De Nemours And Company |
Fungicidal pyrazolones
|
|
BR112012015721A2
(pt)
|
2009-12-30 |
2017-09-26 |
Avila Therapeutics Inc |
modificação covalente de proteínas dirigida por ligante
|
|
US9630956B2
(en)
|
2010-05-12 |
2017-04-25 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526539A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用なピラジン
|
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
CN102947272A
(zh)
|
2010-05-12 |
2013-02-27 |
沃泰克斯药物股份有限公司 |
用作atr激酶抑制剂的2-氨基吡啶衍生物
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2011143425A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2011156626A1
(en)
|
2010-06-09 |
2011-12-15 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
CA2803802A1
(en)
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
WO2011163610A2
(en)
*
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
DK2597955T3
(en)
*
|
2010-07-30 |
2016-03-14 |
Onco Therapy Science Inc |
QUINOLINE DERIVATIVES AND MILK INHIBITORS CONTAINING THESE
|
|
JP2013536192A
(ja)
*
|
2010-08-09 |
2013-09-19 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
組み合わせ
|
|
WO2012068096A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
EP2640367A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
US20130317037A1
(en)
*
|
2010-11-16 |
2013-11-28 |
Glaxosmithkline Intellectual Property Development Limited |
Method of administration and treatment
|
|
MX2013005668A
(es)
*
|
2010-11-19 |
2013-11-04 |
Glaxosmithkline Ip No 2 Ltd |
Metodo de tratamiento con inhibidor de braf.
|
|
EP2643316A2
(en)
|
2010-11-24 |
2013-10-02 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
|
WO2012116237A2
(en)
*
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
ES2609578T3
(es)
|
2011-03-04 |
2017-04-21 |
Glaxosmithkline Intellectual Property Development Limited |
Amino-quinolinas como inhibidores de quinasa
|
|
US9051305B2
(en)
|
2011-03-08 |
2015-06-09 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
MX2013011450A
(es)
|
2011-04-05 |
2014-02-03 |
Vertex Pharma |
Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
JP2014513104A
(ja)
*
|
2011-04-29 |
2014-05-29 |
エクセリクシス， インク． |
Ｐｉ３ｋ／ｍｔｏｒのピリドピリミジノン阻害剤を用いたリンパ腫の治療方法
|
|
WO2012178124A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2012178123A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
|
BR112014007721B1
(pt)
|
2011-09-30 |
2022-11-01 |
Vertex Pharmaceuticals Incorporated |
Processos para preparar compostos úteis como inibidores de atr quinase
|
|
KR102056586B1
(ko)
|
2011-09-30 |
2019-12-18 |
버텍스 파마슈티칼스 인코포레이티드 |
Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
CA2850564A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
AU2012331289B2
(en)
|
2011-11-04 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
New aryl-quinoline derivatives
|
|
WO2013071085A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
EP2776422A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071094A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
|
US9822108B2
(en)
|
2012-01-13 |
2017-11-21 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
CN104093408A
(zh)
*
|
2012-02-06 |
2014-10-08 |
葛兰素史克知识产权第二有限公司 |
用于治疗纤维化疾病的pi3k抑制剂
|
|
EP2812003A1
(en)
*
|
2012-02-06 |
2014-12-17 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pi3k inhibitors for treating cough
|
|
EP2828245A1
(en)
|
2012-03-21 |
2015-01-28 |
Rutgers, The State University of New Jersey |
Antimicrobial agents
|
|
AU2013243291B2
(en)
|
2012-04-05 |
2018-02-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase and combination therapies thereof
|
|
EP2863920B1
(en)
|
2012-06-20 |
2023-03-22 |
Eutropics Pharmaceuticals, Inc. |
Quinoline derivatives for use in the tratment of breast cancer
|
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
AR092530A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
CN103497177B
(zh)
*
|
2012-09-29 |
2017-03-22 |
天津滨江药物研发有限公司 |
作为c‑Met抑制剂的氨基芳香杂环类化合物及其制备方法
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
CN103788071A
(zh)
*
|
2012-11-01 |
2014-05-14 |
中国人民解放军第二军医大学 |
N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
|
|
US20160038503A1
(en)
|
2012-11-21 |
2016-02-11 |
David Richard |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
|
|
LT3486245T
(lt)
|
2012-12-07 |
2021-08-25 |
Vertex Pharmaceuticals Incorporated |
2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius
|
|
TWI630203B
(zh)
|
2013-02-21 |
2018-07-21 |
葛蘭素史克智慧財產發展有限公司 |
做為激酶抑制劑的喹唑啉類
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
CN104098542A
(zh)
*
|
2013-04-11 |
2014-10-15 |
苏州朗信医药科技有限公司 |
一种6-溴代-4-(4-吡嗪基)喹啉的制备方法
|
|
US10732182B2
(en)
|
2013-08-01 |
2020-08-04 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
|
BR112016003229A8
(pt)
|
2013-09-22 |
2020-02-04 |
Calitor Sciences Llc |
composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
|
CN104557955B
(zh)
*
|
2013-10-23 |
2017-05-03 |
上海汇伦生命科技有限公司 |
作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
|
|
AU2014342269B2
(en)
|
2013-10-30 |
2020-02-27 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
|
US9458150B2
(en)
|
2013-11-08 |
2016-10-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
KR102398473B1
(ko)
*
|
2013-11-27 |
2022-05-16 |
시그널켐 라이프사이언시즈 코포레이션 |
Tam 패밀리 키나제 억제제로서의 아미노피리딘 유도체
|
|
CA2932757C
(en)
|
2013-12-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
CN104922116B
(zh)
*
|
2014-03-23 |
2020-08-11 |
上海诗丹德生物技术有限公司 |
甲基丙烯酰基苯并咪唑酮衍生物的用途
|
|
NO2714752T3
(enExample)
*
|
2014-05-08 |
2018-04-21 |
|
|
|
AU2015271030B2
(en)
|
2014-06-05 |
2019-05-16 |
Vertex Pharmaceuticals Incorporated |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
EP3159342B1
(en)
|
2014-06-17 |
2020-08-05 |
Cisen Pharmaceutical Co., Ltd. |
Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
|
|
CN106715456B
(zh)
|
2014-08-12 |
2023-08-29 |
莫纳什大学 |
定向淋巴的前药
|
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
|
PT3180329T
(pt)
|
2014-08-15 |
2020-06-08 |
Janssen Pharmaceuticals Inc |
Triazóis como inibidores do recetor nr2b
|
|
DK3180315T3
(da)
|
2014-08-15 |
2020-04-06 |
Janssen Pharmaceuticals Inc |
Pyrazoler
|
|
ES2870449T3
(es)
|
2014-10-29 |
2021-10-27 |
Bicyclerd Ltd |
Ligandos peptídicos bicíclicos específicos de MT1-MMP
|
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途
|
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
|
CN104961725B
(zh)
*
|
2015-06-18 |
2017-04-19 |
浙江大学 |
4‑α,β不饱和酰胺基喹啉类化合物及制备和应用
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
SI3319963T1
(sl)
*
|
2015-07-09 |
2020-02-28 |
Janssen Pharmaceutica Nv |
Substituirani 4-azaindoli in njihova uporaba kot modulatorji receptorja GLUN2B
|
|
CN108137514A
(zh)
*
|
2015-07-30 |
2018-06-08 |
百时美施贵宝公司 |
芳基取代的二环杂芳基化合物
|
|
WO2017027768A1
(en)
*
|
2015-08-13 |
2017-02-16 |
The Broad Institute, Inc. |
Compositions and methods for treating tuberculosis
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CN114031658A
(zh)
|
2015-09-08 |
2022-02-11 |
莫纳什大学 |
定向淋巴的前药
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
|
RS64114B1
(sr)
|
2015-10-23 |
2023-04-28 |
Navitor Pharm Inc |
Modulatori interakcije sestrin-gator2 i nјihova upotreba
|
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
|
WO2017101829A1
(zh)
*
|
2015-12-16 |
2017-06-22 |
辰欣药业股份有限公司 |
吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体
|
|
EP3414233A1
(en)
|
2016-02-10 |
2018-12-19 |
Janssen Pharmaceutica NV |
Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
|
|
WO2017147316A1
(en)
|
2016-02-25 |
2017-08-31 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and intermediates
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
EP3884939B1
(en)
|
2016-03-09 |
2023-10-25 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
EP3471726A4
(en)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
|
EP3500569B1
(en)
*
|
2016-08-16 |
2022-05-18 |
Merck Patent GmbH |
2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
|
|
TW201819376A
(zh)
|
2016-10-06 |
2018-06-01 |
比利時商健生藥品公司 |
經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
|
|
TWI825663B
(zh)
|
2016-10-14 |
2023-12-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
|
CN106580986B
(zh)
*
|
2016-11-28 |
2017-09-15 |
王保亮 |
一种治疗少弱精子症的药物组合物
|
|
EP3548005A4
(en)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US20180153922A1
(en)
|
2016-12-06 |
2018-06-07 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
|
|
EP3559018A1
(en)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
EP3560921B1
(en)
*
|
2016-12-26 |
2024-08-14 |
Institute Of Materia Medica, Chinese Academy Of Medical Sciences |
Quinazoline compound, preparation method, application as pi3k inhibitor for the treatment of cancer, and pharmaceutical compostion thereof
|
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
AR111233A1
(es)
|
2017-03-08 |
2019-06-19 |
Nimbus Lakshmi Inc |
Inhibidores de tyk2, usos y métodos para la producción de los mismos
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
WO2018183917A1
(en)
|
2017-03-30 |
2018-10-04 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and synthetic intermediates
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
JP7179015B2
(ja)
|
2017-04-26 |
2022-11-28 |
ナビター ファーマシューティカルズ， インコーポレイテッド |
Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
|
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
EP3628044B1
(en)
*
|
2017-05-15 |
2023-11-22 |
The Regents of The University of Michigan |
Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
|
|
US10899798B2
(en)
|
2017-06-26 |
2021-01-26 |
Bicyclerd Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
DK3658557T3
(da)
|
2017-07-28 |
2024-07-29 |
Takeda Pharmaceuticals Co |
Tyk2-inhibitorer og anvendelser deraf
|
|
WO2019025811A1
(en)
|
2017-08-04 |
2019-02-07 |
Bicycletx Limited |
SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
|
|
EP3668550A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
CN107793404A
(zh)
*
|
2017-11-07 |
2018-03-13 |
全椒先奇医药科技有限公司 |
一种治疗缺血性脑损伤药物组合物及其应用
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
IL301089A
(en)
|
2018-01-29 |
2023-05-01 |
Vertex Pharma |
GCN2 inhibitors and their uses
|
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
WO2019169001A1
(en)
|
2018-02-27 |
2019-09-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
PE20251292A1
(es)
*
|
2018-03-08 |
2025-05-14 |
Incyte Corp |
Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
|
|
EP3774732A4
(en)
|
2018-04-04 |
2022-02-09 |
Janssen Pharmaceutica NV |
PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
|
|
HUE058746T2
(hu)
|
2018-04-24 |
2022-09-28 |
Merck Patent Gmbh |
Antiproliferációs vegyületek és felhasználásuk
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
EP3807248A4
(en)
*
|
2018-05-29 |
2021-10-27 |
Council of Scientific and Industrial Research |
BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
|
|
EP3575305A1
(fr)
*
|
2018-05-31 |
2019-12-04 |
Biocidal Alternative Solutions |
Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
|
|
HUE067446T2
(hu)
|
2018-06-15 |
2024-10-28 |
Janssen Pharmaceutica Nv |
Rapamicin analógok és alkalmazásaik
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
KR102595520B1
(ko)
*
|
2018-07-05 |
2023-10-30 |
엘지디스플레이 주식회사 |
헤테로아릴기를 가진 벤즈아졸 유도체 및 이를 포함하는 유기전계발광소자
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス， インコーポレイテッド |
Ｅｉｆ４ｅ阻害剤およびその使用
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
CN113271938A
(zh)
|
2018-11-30 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
PH12021500026A1
(en)
|
2018-11-30 |
2022-05-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
EP3976027B1
(en)
*
|
2019-05-30 |
2025-11-05 |
Merck Sharp & Dohme LLC |
Quinoline derivatives as factor xi activation inhibitors
|
|
BR112021024224A2
(pt)
|
2019-05-31 |
2022-04-26 |
Ikena Oncology Inc |
Inibidores de tead e usos dos mesmos
|
|
US12521438B2
(en)
|
2019-06-10 |
2026-01-13 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
EP3983073A1
(en)
|
2019-06-14 |
2022-04-20 |
Janssen Pharmaceutica NV |
Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
|
|
PH12021552839A1
(en)
|
2019-06-14 |
2022-10-03 |
Janssen Pharmaceutica Nv |
Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
|
|
EP3983413A1
(en)
|
2019-06-14 |
2022-04-20 |
Janssen Pharmaceutica NV |
Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
|
|
CA3142998A1
(en)
|
2019-06-14 |
2020-12-17 |
Janssen Pharmaceutica Nv |
Pyrazine carbamates and their use as glun2b receptor modulators
|
|
PE20220386A1
(es)
|
2019-06-14 |
2022-03-18 |
Janssen Pharmaceutica Nv |
Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
|
|
AU2020293584A1
(en)
|
2019-06-14 |
2022-01-20 |
Janssen Pharmaceutica Nv |
Pyridine carbamates and their use as GluN2B receptor modulators
|
|
SG11202112405VA
(en)
|
2019-06-14 |
2021-12-30 |
Janssen Pharmaceutica Nv |
Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
|
PH12022550605A1
(en)
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
|
MX2022005215A
(es)
|
2019-11-01 |
2022-06-08 |
Navitor Pharm Inc |
Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
|
|
IL293549A
(en)
|
2019-12-05 |
2022-08-01 |
Anakuria Therapeutics Inc |
Rapamycin analogs and uses thereof
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADATION AGENTS AND THEIR USES
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
|
US20210268115A1
(en)
|
2020-02-05 |
2021-09-02 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
|
CN115515685B
(zh)
|
2020-03-03 |
2025-04-08 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
|
MX2022011602A
(es)
|
2020-03-19 |
2023-01-04 |
Kymera Therapeutics Inc |
Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
|
|
WO2021202731A1
(en)
|
2020-03-31 |
2021-10-07 |
Chemocentryx, Inc. |
Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
TW202233612A
(zh)
|
2020-10-23 |
2022-09-01 |
美商林伯士科羅索公司 |
Ctps1抑制劑及其用途
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
KR20230143632A
(ko)
|
2020-12-30 |
2023-10-12 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
IL304907A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
Irak4 degraders and uses thereof
|
|
EP4295850A4
(en)
|
2021-02-16 |
2025-03-05 |
Ribotech Co., Ltd. |
COMPOUND FOR INHIBITING NONSENSE-MEDIATED mRNA DEGRADATION
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
KR20230158659A
(ko)
*
|
2021-03-18 |
2023-11-21 |
쑤저우 궈쾅 팜테크 코포레이션 리미티드 |
Ctla-4 소분자 분해제 및 그 응용
|
|
EP4313989A4
(en)
|
2021-03-29 |
2025-03-05 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
BR112023020781A2
(pt)
|
2021-04-09 |
2023-12-19 |
Nimbus Clio Inc |
Moduladores de cbl-b e usos dos mesmos
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
TW202309030A
(zh)
|
2021-05-07 |
2023-03-01 |
美商凱麥拉醫療公司 |
Cdk2降解劑及其用途
|
|
CN115353512B
(zh)
*
|
2021-07-30 |
2025-07-08 |
上海翊石医药科技有限公司 |
一种杂环脲类化合物及其制备方法和用途
|
|
CN113416181B
(zh)
*
|
2021-08-02 |
2022-05-03 |
四川大学 |
喹唑啉类衍生物及其用途
|
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
WO2023046182A1
(zh)
*
|
2021-09-27 |
2023-03-30 |
广州嘉越医药科技有限公司 |
一种吡啶并[1,2-a]嘧啶酮类化合物的应用
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A2
(en)
|
2022-01-31 |
2024-12-11 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
EP4532470A1
(en)
|
2022-05-25 |
2025-04-09 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CN117402146A
(zh)
*
|
2022-07-13 |
2024-01-16 |
武汉人福创新药物研发中心有限公司 |
杂环并苯环类化合物及其制备方法和用途
|
|
TW202416972A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
經取代之吡啶酮gpr84拮抗劑及其用途
|
|
TW202415650A
(zh)
|
2022-08-02 |
2024-04-16 |
英商利米那生物科技有限公司 |
芳基-三唑基及相關gpr84拮抗劑及其用途
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
CN120457127A
(zh)
*
|
2022-10-20 |
2025-08-08 |
麦克尼斯迪克治疗有限公司 |
用于调节egfr和pi3k的化合物
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116239594B
(zh)
*
|
2023-03-05 |
2023-09-22 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
|
|
EP4620470A3
(en)
|
2023-06-23 |
2025-10-08 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025045915A1
(en)
*
|
2023-08-29 |
2025-03-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods for inducing muscle hypertrophy
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
CN118126038B
(zh)
*
|
2024-05-08 |
2024-07-12 |
烟台大学 |
吡唑并吡啶类衍生物及其制备方法和应用
|